Defence Therapeutics Stock Total Debt
DTCFF Stock | USD 0.82 0.01 1.23% |
Defence Therapeutics fundamentals help investors to digest information that contributes to Defence Therapeutics' financial success or failures. It also enables traders to predict the movement of Defence OTC Stock. The fundamental analysis module provides a way to measure Defence Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Defence Therapeutics otc stock.
Defence |
Defence Therapeutics OTC Stock Total Debt Analysis
Defence Therapeutics' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Competition |
Based on the latest financial disclosure, Defence Therapeutics has a Total Debt of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The total debt for all United States stocks is 100.0% higher than that of the company.
Defence Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Defence Therapeutics' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Defence Therapeutics could also be used in its relative valuation, which is a method of valuing Defence Therapeutics by comparing valuation metrics of similar companies.Defence Therapeutics is currently under evaluation in total debt category among related companies.
Defence Fundamentals
Return On Equity | -4.15 | |||
Return On Asset | -1.79 | |||
Current Valuation | 60.32 M | |||
Shares Outstanding | 37.85 M | |||
Shares Owned By Insiders | 5.26 % | |||
Price To Book | 36.71 X | |||
EBITDA | (7.32 M) | |||
Net Income | (7.34 M) | |||
Cash And Equivalents | 506.7 K | |||
Cash Per Share | 0.01 X | |||
Current Ratio | 0.61 X | |||
Book Value Per Share | (0.03) X | |||
Cash Flow From Operations | (6.04 M) | |||
Earnings Per Share | (0.15) X | |||
Market Capitalization | 143.45 M | |||
Total Asset | 719.67 K | |||
Z Score | -33.0 | |||
Net Asset | 719.67 K |
About Defence Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Defence Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Defence Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Defence Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Defence Therapeutics. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in census. Note that the Defence Therapeutics information on this page should be used as a complementary analysis to other Defence Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Complementary Tools for Defence OTC Stock analysis
When running Defence Therapeutics' price analysis, check to measure Defence Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Defence Therapeutics is operating at the current time. Most of Defence Therapeutics' value examination focuses on studying past and present price action to predict the probability of Defence Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Defence Therapeutics' price. Additionally, you may evaluate how the addition of Defence Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Stocks Directory Find actively traded stocks across global markets |